Tafero EM 200mg/10mg Tablet

Introduction

Tafero EM is a prescription medication that contains two active ingredients: Emtricitabine and Tenofovir disoproxil fumarate. It is available under the brand name Tafero EM. This medication is primarily used in the treatment of HIV-1 infection in adults and adolescents aged 12 years and older.

Uses

Tafero EM is indicated for the treatment of HIV-1 infection. It is used as part of a combination therapy regimen to control the viral load and improve immune function in patients with HIV-1.

Dosage and Administration

The recommended dosage of Tafero EM for adults and adolescents aged 12 years and older is one tablet taken orally once daily, with or without food. Follow the instructions provided by your healthcare provider regarding the dosage and duration of treatment.

Mechanism of Action

Tafero EM contains two active ingredients, Emtricitabine and Tenofovir disoproxil fumarate, which work together to inhibit the reverse transcriptase enzyme, thereby preventing the replication of the HIV-1 virus. This helps reduce the viral load and allows the immune system to function more effectively in fighting the infection.

Side Effects

Common side effects of Tafero EM may include headache, nausea, diarrhea, fatigue, and dizziness. These side effects are usually mild and transient.

However, some patients may experience more serious side effects, such as lactic acidosis (a buildup of lactic acid in the blood) or hepatotoxicity (liver damage). If you experience any severe or persistent side effects, seek medical attention immediately.

Drug Interactions

Tafero EM may interact with other medications, including certain antiviral drugs, antifungal medications, and certain antibiotics. Inform your healthcare provider about all the medications you are taking, including prescription, over-the-counter, and herbal products, to avoid potential drug interactions.

Precautions

Before starting treatment with Tafero EM, inform your healthcare provider about any medical conditions you have, especially kidney problems, liver problems, or bone disorders. This medication may not be suitable for everyone, and your healthcare provider will assess the potential risks and benefits before prescribing it to you.

Tafero EM should not be used in patients with known hypersensitivity to Emtricitabine, Tenofovir disoproxil fumarate, or any of the other ingredients in the medication.

Storage

Patient Tips

• Take Tafero EM exactly as prescribed by your healthcare provider. Do not skip doses or alter the dosage without consulting your doctor.
• continue taking this medication even if you feel well, as stopping treatment may allow the virus to become resistant to the medication.
• If you miss a dose, take it as soon as you remember. However, if it is close to the time for your next dose, skip the missed dose and resume your regular dosing schedule.
• Avoid sharing needles or other injection equipment, as this can increase the risk of HIV transmission.
• Practice safe sex by using barrier methods, such as condoms, to reduce the risk of HIV transmission to your partner.
• Regularly monitor your kidney function and bone density while taking Tafero EM, as this medication may affect these parameters.
• If you have any questions or concerns about your treatment with Tafero EM, don’t hesitate to consult your healthcare provider for guidance.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Ferrous fumarate: medicine to treat iron deficiency anaemia (NHS UK) [Accessed 16 Jun. 2024] (online) Available at:
• Biktarvy 30 mg/120 mg/15 mg film-coated tablets (Health Professionals SmPC) Available at:
• Emtricitabine (Drugs.com) [Accessed 7 Jun. 2024] (online) Available at:
• biktarvy 50 mg-200 mg-25 mg tablet emtricitabine (RX) [Accessed 9 Jun. 2024] (online) Available at:
• Emtricitabine, Rilpivirine, and Tenofovir (MedlinePlus) [Accessed 22 Jun. 2024] (online) Available at:
• Al-Majed AA, Bakheit AHH, Al-Qahtani BM, Al-Kahtani HM, Abdelhameed AS. Emtricitabine. Profiles Drug Subst Excip Relat Methodol. 2020;45:55-91. doi: 10.1016/bs.podrm.2019.10.003. Epub 2019 Dec 6. [Accessed 6 Jun. 2024] Available at: